Home The Word Brain My Amedeo FAQ Privacy About   

2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Free Subscription


1 Ann Intern Med
1 Arch Virol
1 Clin Infect Dis
2 J Immunol
2 J Infect
3 J Infect Dis
1 J Virol
1 MMWR Morb Mortal Wkly Rep
2 Nat Immunol
2 Nat Med
2 Pediatr Infect Dis J
1 Pediatrics
1 PLoS Med
6 PLoS One
19 Vaccine
1 Virus Res

  Retrieve available abstracts of this week’s articles:
HTML format
Single Articles

    Ann Intern Med

  1. ZERBO O, Bartlett J, Fireman B, Lewis N, et al
    Effectiveness of Recombinant Zoster Vaccine Against Herpes Zoster in a Real-World Setting.
    Ann Intern Med. 2024 Jan 9. doi: 10.7326/M23-2023.
    PubMed         Abstract available

    Arch Virol

  2. SPRYGIN A, van Schalkwyk A, Mazloum A, Byadovskaya O, et al
    Genome sequence characterization of the unique recombinant vaccine-like lumpy skin disease virus strain Kurgan/2018.
    Arch Virol. 2024;169:23.
    PubMed         Abstract available


  3. JAY R
    NHS eligibility criteria for shingles vaccination is ageist.
    BMJ. 2024;384:p2991.

    Clin Infect Dis

  4. CHANDLER R, Montenegro N, Llorach C, Aguirre LN, et al
    Immunogenicity, Reactogenicity, and Safety of AS01E-adjuvanted RSV Prefusion F Protein-based Candidate Vaccine (RSVPreF3 OA) When Co-administered With a Seasonal Quadrivalent Influenza Vaccine in Older Adults: Results of a Phase 3, Open-Label, Randomi
    Clin Infect Dis. 2024 Jan 8:ciad786. doi: 10.1093.
    PubMed         Abstract available

    J Immunol

  5. ZHENG YY, Zhao L, Wei XF, Sun TZ, et al
    Vaccine Molecule Design Based on Phage Display and Computational Modeling against Rhabdovirus.
    J Immunol. 2024 Jan 10:ji2300447. doi: 10.4049/jimmunol.2300447.
    PubMed         Abstract available

  6. HORTA AL, Gigley J, Boutet M, Lavau G, et al
    Memory-like NK Cells Are a Critical Component of Vaccine-Induced Immunity to Trypanosoma cruzi Infection.
    J Immunol. 2024 Jan 10:ji2300509. doi: 10.4049/jimmunol.2300509.
    PubMed         Abstract available

    J Infect

  7. BRENDISH NJ, Davis C, Chapman ME, Borca F, et al
    Emergency Department point-of-care antiviral host response testing is accurate during periods of multiple respiratory virus co-circulation.
    J Infect. 2023 Nov 15:S0163-4453(23)00556-X. doi: 10.1016/j.jinf.2023.
    PubMed         Abstract available

  8. LIECHTI FD, Bijlsma MW, Brouwer MC, van Sorge NM, et al
    Impact of the COVID-19 pandemic on incidence and serotype distribution of pneumococcal meningitis - A prospective, nationwide cohort study from the Netherlands.
    J Infect. 2023 Nov 8:S0163-4453(23)00555-8. doi: 10.1016/j.jinf.2023.

    J Infect Dis

  9. CARROLL TD, Wong T, Morris MK, Di Germanio C, et al
    Vaccine-Boosted CCP Decreases Virus Replication and Hastens Resolution of Infection Despite Transiently Enhancing Disease in SARS-CoV-2-Infected Hamsters.
    J Infect Dis. 2024 Jan 12:jiad568. doi: 10.1093.
    PubMed         Abstract available

  10. HARRER CE, Mayer L, Fathi A, Lassen S, et al
    Identification of a spike-specific CD8+ T cell epitope following vaccination against the Middle East respiratory syndrome coronavirus in humans.
    J Infect Dis. 2024 Jan 9:jiad612. doi: 10.1093.
    PubMed         Abstract available

  11. HOWARD LM, Jensen TL, Goll JB, Gelber CE, et al
    Metabolomic Signatures Differentiate Immune Responses in Avian Influenza Vaccine Recipients.
    J Infect Dis. 2024 Jan 5:jiad611. doi: 10.1093.
    PubMed         Abstract available

    J Virol

  12. TU JJ, King E, Maksimova V, Smith S, et al
    An HTLV-1 envelope mRNA vaccine is immunogenic and protective in New Zealand rabbits.
    J Virol. 2024 Jan 9:e0162323. doi: 10.1128/jvi.01623.
    PubMed         Abstract available


  13. MARKS P, Califf R
    Is Vaccination Approaching a Dangerous Tipping Point?
    JAMA. 2024 Jan 5. doi: 10.1001/jama.2023.27685.

    MMWR Morb Mortal Wkly Rep

  14. PAYNE AB, Novosad S, Wiegand RE, Najdowski M, et al
    Effectiveness of Bivalent mRNA COVID-19 Vaccines in Preventing COVID-19-Related Thromboembolic Events Among Medicare Enrollees Aged >/=65 Years and Those with End Stage Renal Disease - United States, September 2022-March 2023.
    MMWR Morb Mortal Wkly Rep. 2024;73:16-23.
    PubMed         Abstract available

    Nat Immunol

  15. Baseline immune characteristics linked to pneumococcal vaccine responsiveness in older adults.
    Nat Immunol. 2024 Jan 5. doi: 10.1038/s41590-023-01737.

  16. RAVICHANDRAN S, Erra-Diaz F, Karakaslar OE, Marches R, et al
    Distinct baseline immune characteristics associated with responses to conjugated and unconjugated pneumococcal polysaccharide vaccines in older adults.
    Nat Immunol. 2024 Jan 5. doi: 10.1038/s41590-023-01717.
    PubMed         Abstract available

    Nat Med

  17. PANT S, Wainberg ZA, Weekes CD, Furqan M, et al
    Lymph-node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: the phase 1 AMPLIFY-201 trial.
    Nat Med. 2024 Jan 9. doi: 10.1038/s41591-023-02760.
    PubMed         Abstract available

  18. TAYLOR TE, Osier F
    Integrating vaccines and monoclonal antibodies into malaria prevention.
    Nat Med. 2024 Jan 10. doi: 10.1038/s41591-023-02745.

    Pediatr Infect Dis J

  19. SHEN Y, Zhang N, Xu S, Zhao S, et al
    Bacillus Calmette-Guerin Vaccine-induced Mycobacterial Spindle Cell Pseudotumor in an Infant.
    Pediatr Infect Dis J. 2023 Nov 20. doi: 10.1097/INF.0000000000004166.

  20. GALIZA EP, Khalil A, Heath PT
    Update on Vaccines in Antenatal Care.
    Pediatr Infect Dis J. 2023 Dec 27. doi: 10.1097/INF.0000000000004183.


  21. POUKKA E, Andersson NW, Thiesson EM, Baum U, et al
    COVID-19 Vaccine Effectiveness Among Adolescents.
    Pediatrics. 2024 Jan 10:e2023062520. doi: 10.1542/peds.2023-062520.
    PubMed         Abstract available

    PLoS Med

  22. GHARPURE R, Chard AN, Cabrera Escobar M, Zhou W, et al
    Costs and cost-effectiveness of influenza illness and vaccination in low- and middle-income countries: A systematic review from 2012 to 2022.
    PLoS Med. 2024;21:e1004333.
    PubMed         Abstract available

    PLoS One

  23. SETIAWAN D, Nurulita NA, Khoirunnisa SM, Postma MJ, et al
    The clinical effectiveness of one-dose vaccination with an HPV vaccine: A meta-analysis of 902,368 vaccinated women.
    PLoS One. 2024;19:e0290808.
    PubMed         Abstract available

  24. AL-KAIF LAIK, Al-Ameri H, Alfatlawi WRO, Mahdi AE, et al
    Detection of CTLA-4 level and humeral immune response after the second dose of COVID-19 vaccine in certain Iraqi provinces participants.
    PLoS One. 2024;19:e0296521.
    PubMed         Abstract available

  25. ETERAFI M, Fouladi N, Golizadeh M, Shaker H, et al
    Reported side-effects following Oxford/AstraZeneca COVID-19 vaccine in the north-west province, Iran: A cross-sectional study.
    PLoS One. 2024;19:e0296669.
    PubMed         Abstract available

    Trumpism, climate and COVID: Social bases of the new science rejection.
    PLoS One. 2024;19:e0293059.
    PubMed         Abstract available

  27. Expression of Concern: Split inactivated COBRA vaccine elicits protective antibodies against H1N1 and H3N2 influenza viruses.
    PLoS One. 2024;19:e0297253.

  28. SAFARI D, Daningrat WOD, Milucky JL, Khoeri MM, et al
    Nasopharyngeal carriage of Streptococcus pneumoniae among children <5 years of age in Indonesia prior to pneumococcal conjugate vaccine introduction.
    PLoS One. 2024;19:e0297041.
    PubMed         Abstract available


  29. KNIJFF M, van Lier A, Boer M, de Vries M, et al
    Parental intention, attitudes, beliefs, trust and deliberation towards childhood vaccination in the Netherlands in 2022: Indications of change compared to 2013.
    Vaccine. 2024 Jan 11:S0264-410X(23)01539-6. doi: 10.1016/j.vaccine.2023.
    PubMed         Abstract available

  30. GOLDIN S, Moen A, Moss WJ, Nuzzo J, et al
    Assessing the relationship between existing childhood, adolescent and adult immunization programmes and national COVID-19 vaccination capacities in 2021.
    Vaccine. 2024 Jan 11:S0264-410X(23)01484-6. doi: 10.1016/j.vaccine.2023.
    PubMed         Abstract available

  31. JOACHIM GE, Wagner AL, Naseem M, Boulton ML, et al
    Trends in childhood vaccination in Pakistan and associated factors; 2006-2018.
    Vaccine. 2024 Jan 10:S0264-410X(24)00015-X. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available

  32. SHARP M, Lozano P, Southworth A, Peters A, et al
    Mixed methods approach to understanding COVID-19 vaccine hesitancy among immigrants in the Chicago.
    Vaccine. 2024 Jan 9:S0264-410X(23)01508-6. doi: 10.1016/j.vaccine.2023.
    PubMed         Abstract available

  33. LIN HH, Wu YS, Chang MT, Shyur LF, et al
    Plant-derived galactolipids enhance specific antibody production and induce class-switch as vaccine adjuvant.
    Vaccine. 2024 Jan 9:S0264-410X(24)00002-1. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available

  34. HINSON-ENSLIN AM, Espinoza LE
    The mental health symptoms of individuals with sensory disabilities and the reasons that lead to COVID-19 vaccine refusal and hesitancy.
    Vaccine. 2024 Jan 9:S0264-410X(24)00012-4. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available

  35. MULLER MP, Navarro C, Wilson SE, Shulha HP, et al
    Prospective monitoring of adverse events following vaccination with Modified vaccinia Ankara - Bavarian Nordic (MVA-BN) administered to a Canadian population at risk of Mpox: A Canadian Immunization Research Network study.
    Vaccine. 2024 Jan 9:S0264-410X(23)01514-1. doi: 10.1016/j.vaccine.2023.
    PubMed         Abstract available

  36. OKUMOTO A, Nomura Y, Okuda S, Shikano M, et al
    Issues with infectious disease vaccine introduction into routine vaccination in Japan, and considerations for accelerating the process.
    Vaccine. 2024 Jan 9:S0264-410X(23)01504-9. doi: 10.1016/j.vaccine.2023.
    PubMed         Abstract available

  37. CARROLL JC, Herbert SMC, Nguyen TQ, Schork CJ, et al
    Vaccination equity and the role of community pharmacy in the United States: A qualitative study.
    Vaccine. 2024 Jan 8:S0264-410X(23)01509-8. doi: 10.1016/j.vaccine.2023.
    PubMed         Abstract available

  38. BUHL C, Jacobsen R, Almarsdottir AB, Abtahi S, et al
    Public's perspective on COVID-19 adenovirus vector vaccines after thrombosis with thrombocytopenia syndrome (TTS) reports and associated regulatory actions - A cross-sectional study in six EU member states.
    Vaccine. 2024 Jan 4:S0264-410X(23)01511-6. doi: 10.1016/j.vaccine.2023.
    PubMed         Abstract available

  39. KRANZLER EC, Ihongbe TO, Marshall MC, Denison B, et al
    Racial and ethnic differences in COVID-19 vaccine readiness among adults in the United States, January 2021-April 2023.
    Vaccine. 2024 Jan 4:S0264-410X(23)01537-2. doi: 10.1016/j.vaccine.2023.
    PubMed         Abstract available

  40. ENYINNAYA JC, Anderson AA, Kelp NC, Long M, et al
    The Social Ecology of Health Beliefs and Misinformation Framework: Examining the impact of misinformation on vaccine uptake through individual and sociological factors.
    Vaccine. 2024 Jan 5:S0264-410X(24)00001-X. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available

  41. REIS JN, Azevedo J, de Oliveira AML, Menezes APO, et al
    Long-term surveillance of invasive pneumococcal disease: The impact of 10-valent pneumococcal conjugate vaccine in the metropolitan region of Salvador, Brazil.
    Vaccine. 2024 Jan 5:S0264-410X(23)01501-3. doi: 10.1016/j.vaccine.2023.
    PubMed         Abstract available

  42. STONE ND, Parker Fiebelkorn A, Guo A, Mothershed E, et al
    Challenges and opportunities during the COVID-19 vaccination efforts in long-term care.
    Vaccine. 2024 Jan 5:S0264-410X(23)01510-4. doi: 10.1016/j.vaccine.2023.
    PubMed         Abstract available

  43. DOBROVOLSKIENE N, Balevicius R, Mlynska A, Zilionyte K, et al
    Immunomodulatory properties of bacteriophage derived dsRNA of different size and their use as anticancer vaccine adjuvants.
    Vaccine. 2024 Jan 5:S0264-410X(23)01518-9. doi: 10.1016/j.vaccine.2023.
    PubMed         Abstract available

  44. STELETOU E, Giannouchos T, Dimitriou G, Karatza A, et al
    Parental concerns and vaccine hesitancy against COVID-19 vaccination for children in Greece: A cross-sectional survey.
    Vaccine. 2024 Jan 6:S0264-410X(24)00003-3. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available

  45. COSTA M, Mansilla F, Manuel Sala J, Saravia A, et al
    Fasciola hepatica infection modifies IgG1 specific immune response to foot-and-mouse disease virus induced by vaccination.
    Vaccine. 2024 Jan 6:S0264-410X(23)01513-X. doi: 10.1016/j.vaccine.2023.
    PubMed         Abstract available

  46. ROZENBAUM MH, Huang L, Perdrizet J, Cane A, et al
    Cost-effectiveness of 20-valent pneumococcal conjugate vaccine in US infants.
    Vaccine. 2024 Jan 7:S0264-410X(23)01503-7. doi: 10.1016/j.vaccine.2023.
    PubMed         Abstract available

  47. QURESHI NS, Miller LG, Judge SP, Tran NDT, et al
    Characterizing predictors of COVID-19 vaccine refusal in an urban southern California jail population.
    Vaccine. 2024 Jan 9:S0264-410X(24)00017-3. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available

    Virus Res

  48. ZAHEDIPOUR F, Zahedipour F, Zamani P, Jaafari MR, et al
    Harnessing CRISPR Technology for Viral Therapeutics and Vaccines: From Preclinical Studies to Clinical Applications.
    Virus Res. 2024 Jan 9:199314. doi: 10.1016/j.virusres.2024.199314.
    PubMed         Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Vaccines is free of charge.